Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2243-2253

  Gámez Pozo, Angelo ^a   Berges Soria, Julia ^a   Arevalillo, Jorge M ^b   Nanni, Paolo ^c   López Vacas, Rocío ^a   Navarro, Hilario ^b   Grossmann, Jonas ^c   Castaneda, Carlos A ^d   Main, Paloma ^e   Díaz Almirón, Mariana ^a   Espinosa, Enrique ^a   Ciruelos, Eva ^f   Fresno Vara, Juan Ángel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MICRORNA; RNA; ESTROGEN RECEPTOR ALPHA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMS BIOLOGY; TANDEM MASS SPECTROMETRY; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MASS SPECTROMETRY; MCF 7 CELL LINE; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASS SPECTROMETRY; MCF-7 CELLS; MICRORNAS; MIDDLE AGED; PROTEOMICS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84939418932     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1937     Document Type: Article

References (56)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49: 1374-403.
2. Espinosa E, Gamez-Pozo A, Sanchez-Navarro I, Pinto A, Castaneda CA, Ciruelos E, et al. The present and future of gene profiling in breast cancer. Cancer Metastasis Rev 2012;31:41-6.
3. Mann M, Kelleher NL. Precision proteomics: the case for high resolution and high mass accuracy. Proc Natl Acad Sci U S A 2008;105:18132-8.
4. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
5. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012;13:358-69.
6. Gamez-Pozo A, Sanchez-Navarro I, Calvo E, Diaz E, Miguel-Martin M, Lopez R, et al. Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches. Mol Biosyst 2011;7:2368-74.
7. SprungRWJr, Brock JW, Tanksley JP, LiM, Washington MK, Slebos RJ, et al. Equivalence of protein inventories obtained from formalin-fixed paraffinembedded and frozen tissue in multidimensional liquid chromatographytandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics 2009;8:1988-98.
8. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, et al. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near totalmRNA degradation. Br J Cancer 2012;107:684-94.
9. Liu S, Im H, Bairoch A, Cristofanilli M, Chen R, Deutsch EW, et al. A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17. J Proteome Res 2013;12: 45-57.
10. Gamez-Pozo A, Ferrer NI, Ciruelos E, Lopez-Vacas R, Martinez FG, Espinosa E, et al. Shotgun proteomics of archival triple-negative breast cancer samples. Proteomics Clin Appl 2013;7:283-91.
11. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8: 118-27.
12. Sanchez-Navarro I, Gamez-Pozo A, Gonzalez-Baron M, Pinto-Marin A, Hardisson D, Lopez R, et al. Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalinfixed, paraffin-embedded breast cancer tissues. Biotechniques 2010;48: 389-97.
13. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011;44:839-47.
14. Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
15. Lauritzen S. Graphical models. Oxford, United Kingdom: Oxford University Press; 1996.
16. Chow CK, Liu CN. Approximating discrete probability distributions with dependence trees. IEEE Trans Inform Theory 1968;14:462-7.
17. Kruskal JB. On the shortest spanning subtree of a graph and the traveling salesman problem. Proc Am Math Soc 1956;7:48-50.
18. Cover TM, Thomas JA. Elements of information theory. 2nd ed. New York: Wiley Interscience; 2006.
19. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
20. Abreu GCG, Edwards D, Labouriau R. High-dimensional graphical model search with the gRapHD R package. J StatSoftw 2010;37:1-18.
21. Miller LD, Coffman LG, Chou JW, BlackMA, Bergh J, D'Agostino R Jr, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011;71:6728-37.
22. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, et al. A refined molecular taxonomy of breast cancer. Oncogene 2012;31: 1196-206.
23. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
24. Wang M, Weiss M, Simonovic M, Haertinger G, Schrimpf SP, Hengartner MO, et al. PaxDb, a database of protein abundance averages across all three domains of life. Mol Cell Proteomics 2012;11:492-500.
25. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011;476:346-50.
26. Dennison JB, Molina JR, Mitra S, Gonzalez-Angulo AM, Balko JM, Kuba MG, et al. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2013;19: 3703-13.
27. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol 2011;32: 441-50.
28. Cook KL, Shajahan AN, Warri A, Jin L, Hilakivi-Clarke LA, Clarke R. Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res 2012;72: 3337-49.
29. Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA, et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer 2003;88:579-85.
30. Baniwal SK, Chimge NO, Jordan VC, Tripathy D, Frenkel B. Prolactininduced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS ONE 2013;8: e62361.
31. Descotes F, Jezequel P, Spyratos F, Campion L, Grenot C, Lerebours F, et al. Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study. Int J Oncol 2012;41:92-104.
32. Marguerat S, Schmidt A, Codlin S, Chen W, Aebersold R, Bahler J. Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell 2012;151:671-83.
33. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11:R27.
34. He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R, et al. miR-342 is associated with estrogen receptor-alpha expression and response to tamoxifen in breast cancer. Exp Ther Med 2013;5:813-8.
35. Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, Mansouri F, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev 2012;13:873-7.
36. Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies newmarkers of chemoresistance of triple-negative breast cancer. PLoSONE 2014;9:e96228.
37. Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP, et al. Validation of expression patterns for nine miRNAs in 204 lymphnode negative breast cancers. PLoS ONE 2012;7:e48692.
38. Wiley HS. Integrating multiple types of data for signaling research: challenges and opportunities. Sci Signal 2011;4:pe9.
39. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010;26:i237-45.
40. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et al. Micro- RNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011;71:2926-37.
41. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Silva-Jr WA, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res 2007;40:1435-40.
42. Rakesh K, Agrawal DK. Cytokines and growth factors involved in apoptosis and proliferation of vascular smooth muscle cells. Int Immunopharmacol 2005;5:1487-506.
43. Liu NQ, Dekker LJ, Stingl C, Guzel C, De Marchi T, Martens JW, et al. Quantitative proteomic analysis of microdissected breast cancer tissues: comparison of label-free and SILAC-based quantification with shotgun, directed, and targeted MS approaches. J Proteome Res 2013; 12:4627-41.
44. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 2013;23:316-31.
45. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
46. Jones NP, Schulze A. Targeting cancer metabolism-aiming at a tumour's sweet-spot. Drug Discov Today 2012;17:232-41.
47. McClelandML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 2012;72:5812-23.
48. Lu W, Pelicano H, Huang P. Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell 2010;18:199-200.
49. Budczies J, Pfitzner BM, Györffy B, Winzer KJ, Radke C, Dietel M, et al. Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer 2015;136:1619-28.
50. Cao MD, Lamichhane S, Lundgren S, Bofin A, Fjosne H, Giskeodegard GF, et al. Metabolic characterization of triple negative breast cancer. BMC Cancer 2014;14:941.
51. Kim S, Kim do H, Jung WH, Koo JS. Expression of glutamine metabolismrelated proteins according to molecular subtype of breast cancer. Endocr Relat Cancer 2013;20:339-48.
52. Hu CA, Khalil S, Zhaorigetu S, Liu Z, Tyler M, Wan G, et al. Human Delta1- pyrroline-5-carboxylate synthase: function and regulation. Amino Acids 2008;35:665-72.
53. Dang CV. Links between metabolism and cancer. Genes Dev 2012;26: 877-90.
54. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009;69: 7986-93.
55. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010;29:313-24.
56. Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, et al. MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS ONE 2013;8:e64759.